A Hub for Regulatory, Compliance, and Business Insights
Peptide therapies are moving quickly from a niche compounding category into one of the most closely watched corners of healthcare, with the FDA’s Pharmacy Compounding Advisory Committee, state boards of pharmacy, and private litigants all sharpening their focus on how these products are manufactured, marketed, and prescribed. Frier Levitt attorneys are at the forefront of this evolving landscape, providing critical insights for compounding pharmacies, telehealth platforms, wellness businesses, and other stakeholders navigating this dynamic space.
This resource hub features our latest webinars and articles covering FDA’s bulk drug substance review process, 503A and 503B compounding compliance, state board enforcement, telehealth and prescribing rules, FTC advertising scrutiny, and business strategies to help you stay informed and compliant amid rapidly evolving developments in the peptide space.
Featured Articles
- FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List – April 16, 2026
The U.S. Food and Drug Administration (FDA) has taken steps that may affect the legal status of popular compounded peptides under section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)… - The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry – March 10, 2026
The peptide compounding market is at an inflection point. Recent comments from U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. suggest that the regulatory window for properly licensed and compliant compounding pharmacies… - FDA Crackdown on Telehealth Advertising: What Your Company Needs to Know About Compounded Drug Marketing Compliance – March 9, 2026
The FDA has increased scrutiny of misleading advertising of compounded drug products. On March 3, 2026, the FDA announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites…
Featured Webinars
- The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models – August 20, 2026
Pharmacy compounding remains one of the most closely watched areas of FDA enforcement, particularly as compounded GLP-1s and peptides continue to draw regulatory and manufacturer attention… - FDA’s July Peptide Review: What the PCAC Meeting Means for Peptide Compounding – July 22, 2026
The peptide industry is approaching one of its most consequential regulatory moments in recent years. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) considers whether seven peptides should be added to the 503A Bulks List.… - Legal Insights into GLP-1 and Peptide Compounding in 2026 – March 18, 2026
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape…
Meet Our Team
Edgar J. Asebey
Partner
973-852-8392
easebey@frierlevitt.com
Jesse C. Dresser
Partner
973-852-8361
jdresser@frierlevitt.com
Guilherme Ferrari Faviero
Senior Associate
332-205-6585
gferrari@frierlevitt.com
Arielle T. Miliambro
Partner
973-852-8379
amiliambro@frierlevitt.com
Brandon S. Zarsky
Partner
973-852-8398
bzarsky@frierlevitt.com
